Healthcare IPOs under the microscope

Author: | Published: 26 Apr 2019

Baker McKenzie reviews the global biotech IPO landscape, considering how regulatory initiatives have aided growth

Last year was a strong year for initial public offerings (IPOs) in the biotechnology sector, with both the amount of capital raised and the volume of IPOs at the second-highest level in the last five years. As of November 2018* there had been 40 biotech IPOs, down slightly on the previous year's record of 44, but capital raised increased 10% to $4.2 billion, a figure only bettered in 2016 when $5.1 billion was raised....